LAPORAN KASUS : HEMATOMA REGIO FEMORALIS PADA PASIEN DENGAN HEMOFILIA A
DOI:
https://doi.org/10.31004/prepotif.v9i3.51829Keywords:
defisiensi faktor VIII, hemofilia A, konsentrat faktor VIII, perdarahan spontanAbstract
Hemofilia A adalah kelainan perdarahan yang disebabkan oleh kekurangan atau tidak adanya faktor koagulasi VIII, yang ditandai dengan perdarahan spontan; perdarahan setelah trauma atau operasi; perdarahan pada sendi atau otot; dan perdarahan jaringan lunak. Kami melaporkan kasus seorang laki- laki berusia 22 tahun datang ke unit gawat darurat dengan keluhan utama perdarahan serta pembengkakan di paha kiri. Pasien memiliki riwayat hemofilia A sedang dan pernah menerima terapi penggantian faktor VIII, namun putus berobat dan tidak menerima terapi faktor VIII selama satu tahun sebelum masuk rumah sakit. Perdarahan berhasil diatasi setelah pemberian 1500 IU konsentrat faktor VIII rekombinan secara intravena. Kasus ini menunjukkan pentingnya terapi penggantian faktor sebagai profilaksis jangka panjang pada pasien hemofilia A.References
Aronstam, A., Rainsford, S. G., & Painter, M. J. (1979). Patterns of bleeding in adolescents with severe haemophilia A. British Medical Journal, 1(6161), 469–470.
Berntorp, E., & Shapiro, A. D. (2012). Modern haemophilia care. The Lancet, 379(9824), 1447–1456. https://doi.org/10.1016/S0140-6736(11)61139-2
Blanchette, V. S., Key, N. S., Ljung, L. R., et al. (2014). Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 12(11), 1935–1939.
Clausen, N., Petrini, P., Claeyssens-Donadel, S., Gouw, S. C., Liesner, R., & PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. (2014). Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia, 20(6), 747–755.
Clinical and Laboratory Standards Institute. (2008). CLSI H47-A2 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test (2nd ed.). Wayne, PA: Author.
Colvin, B. T., Astermark, J., Fischer, K., et al. (2008). European principles of haemophilia care. Haemophilia, 14(2), 361–374.
Dunkley, S., Lam, J. C. M., John, M. J., et al. (2018). Principles of haemophilia care: the Asia- Pacific perspective. Haemophilia, 24(3), 366–375.
Feldman, B. M., Rivard, G. E., Babyn, P., et al. (2018). Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. The Lancet Haematology, 5(6), e252–e260.
Fischer, K., Collins, P. W., Ozelo, M. C., Srivastava, A., Young, G., & Blanchette, V. S. (2016). When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 14(5), 1105–1109.
Gomez, K., Chitlur, M., & GEHEP panel. (2013). Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A. Thrombosis and Haemostasis, 109(4), 738–743.
Kitchen, S., Blakemore, J., Friedman, K. D., et al. (2016). A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. Journal of Thrombosis and Haemostasis, 14(4), 757–764.
Kitchen, S., Signer-Romero, K., & Key, N. S. (2015). Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia, 21(4), 550–557.
Konkle, B. A., Josephson, N. C., & Nakaya Fletcher, S. M. (2017, June 22). Hemophilia A. GeneReviews.
Nijdam, A., Kurnik, K., Liesner, R., et al. (2015). How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia, 21(4), 444–450.
Nilsson, I. M., Berntorp, E., Löfqvist, T., & Pettersson, H. (1992). Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. Journal of Internal Medicine, 232(1), 25–32.
Srivastava, A., Santagostino, E., Dougall, A., et al. (2020). WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 26(Suppl 6), 1–158.
Stephensen, D., Bladen, M., & McLaughlin, P. (2018). Recent advances in musculoskeletal physiotherapy for haemophilia. Therapeutic Advances in Hematology, 9(8), 227–237.
U.S. National Library of Medicine. (2025). DailyMed - advate (antihemophilic factor- recombinant kit). Diakses pada 17 Februari 2025, dari https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fa03d2-cd4c-4155-9b57- 1396c4fa42da
White, G. C., II, Rosendaal, F., Aledort, L. M., et al. (2001). Definitions in hemophilia: recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis, 85(3), 560.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Alister Garcia Himawan, Velma Herwanto, Albert Tri Rustamadji
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
